Boston Scientific enters $2B accelerated share repurchase, expects $0.02 EPS accretion in FY2026

BOSTON SCIENTIFIC CORP

ASR with JPMorgan for $2B; receives ~30.4M shares upfront at $52.68 (80% of repurchase price).
Final settlement expected by June 30, 2026; total shares based on VWAP during term less discount.
After completion, $3B remains under $5B share repurchase authorization.
Expected net impact to adjusted EPS in FY2026 is $0.02 accretive to prior guidance (Apr 22, 2026).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.